Genomic Health Newswire (Page 4)

Comprehensive Real-Time News Feed for Genomic Health. (Page 4)

Results 61 - 80 of 108 in Genomic Health

  1. Genomic Health Announces Positive Results from Latest Clinical...Read the original story

    Sep 29, 2014 | PressReleasePoint

    Genomic Health, Inc. today announced strongly positive results from an additional independent clinical validation study of the Oncotype DXA prostate cancer test, conducted in collaboration with the Uniformed Services University of the Health Sciences' Center for Prostate Disease Research supported by a multi-disciplinary team of investigators under a cooperative research and development agreement with USU. This new large study reconfirmed the biopsy-based test's Genomic Prostate Score as a predictor of adverse pathology at surgery and, for the first time, validated GPS as a strong independent predictor of a rise in prostate-specific antigen following surgery .

    Comment?

  2. Genomic Health announces positive results for validation study of Oncotype DXRead the original story

    Sep 29, 2014 | Theflyonthewall.com

    Genomic Health announces positive results for validation study of Oncotype DX Genomic Health announced strongly positive results from an additional independent clinical validation study of the Oncotype DX prostate cancer test. This new large study reconfirmed the biopsy-based test's Genomic Prostate Score as a predictor of adverse pathology at surgery and, for the first time, validated GPS as a strong independent predictor of a rise in prostate-specific antigen following surgery.

    Comment?

  3. The Oncotype DX Test and Precision Oncology: New Data Presented at...Read the original story

    Sep 29, 2014 | Business Wire

    In line with this year's theme for the annual European Society for Medical Oncology Congress - 'Precision Medicine in Cancer Care' - Genomic Health presented results from multiple studies across different cancer types demonstrating how its genomic test Onco type DX has led to a greater understanding of cancer at the molecular level, enabling more personalised treatment decisions. "The results of this study confirm that the information provided by the Oncotype DX prostate cancer test can help physicians and patients choose the most appropriate treatment approach, based on an individualised risk assessment."

    Comment?

  4. Genomic Health Reports Positive Results from Latest Clinical Validation Study of Oncotype DXRead the original story w/Photo

    Sep 29, 2014 | Benzinga

    Genomic Health, Inc. today announced strongly positive results from an additional independent clinical validation study of the Oncotype DXA prostate cancer test, conducted in collaboration with the Uniformed Services University of the Health Sciences' Center for Prostate Disease Research supported by a multi-disciplinary team of investigators under a cooperative research and development agreement with USU. This new large study reconfirmed the biopsy-based test's Genomic Prostate Score as a predictor of adverse pathology at surgery and, for the first time, validated GPS as a strong independent predictor of a rise in prostate-specific antigen following surgery .

    Comment?

  5. Genomic Health Announces Oral Presentation of Positive Results from...Read the original story

    Sep 26, 2014 | Applied Clinical Trials

    Genomic Health Announces Oral Presentation of Positive Results from Second Large, Independent Clinical Validation Study of Oncotype DX? in DCIS Breast Cancer at 2014 CTRC-AACR San Antonio Breast Cancer Symposium Genomic Health Announces Oral Presentation of Positive Results from Second Large, Independent Clinical Validation Study of Oncotype DX in DCIS Breast Cancer at 2014 CTRC-AACR San Antonio Breast Cancer Symposium /PRNewswire/ -- Genomic Health, Inc. today announced that results from a second large, independent clinical validation study of Oncotype DX in patients with a pre-invasive form of breast cancer known as DCIS will be featured as an oral presentation at the 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium , which is being held predicted the risk of local recurrence, defined as either the development of a new invasive breast cancer or the recurrence of DCIS in the ... (more)

    Comment?

  6. Genomic Health Given "Neutral" Rating at ZacksRead the original story

    Sep 24, 2014 | AmericanBankingNews.com

    ... 's price target suggests a potential upside of 4.71% from the company's current price. Zacks' analyst wrote, "Genomic Health reported a loss of $0.15 per share in the second quarter of 2014, which deteriorated 50% from the year-ago loss figure but ...

    Comment?

  7. New Survey Reveals Alarming Lack of Understanding of Prostate Cancer, ...Read the original story w/Photo

    Sep 24, 2014 | Applied Clinical Trials

    Prostate Cancer Survivor Joe Torre, Three Prominent Advocacy Organizations and Genomic Health Partner to Encourage Men to Seek Genomic Testing to Enable More Confident Treatment Decisions and Avoid Life-altering Side Effects New Survey Reveals Alarming Lack of Understanding of Prostate Cancer, Inspires "Your Prostate Your Decision" Education Campaign with Baseball Hall-of-Famer Joe Torre Prostate Cancer Survivor Joe Torre, Three Prominent Advocacy Organizations and Genomic Health Partner to Encourage Men to Seek Genomic Testing to Enable More Confident Treatment Decisions and Avoid Life-altering Side Effects /PRNewswire/ -- In partnership with Men's Health Network , Prostate Health Education Network , ZERO - the End of Prostate Cancer and , four-time world champion baseball Hall-of-Famer and prostate cancer survivor, Genomic Health, Inc. today launched Your Prostate Your Decision to ... (more)

    Comment?

  8. Big Changes for Molecular Diagnostics as FDA Moves on Lab Developed TestsRead the original story

    Sep 23, 2014 | Bio IT World

    ... mainly by hospital labs to diagnose rare diseases, to an industry where big players like Myriad Genetics and Genomic Health can post profits in the hundreds of millions of dollars. Conventional IVD manufacturers have been crying foul, and the FDA ...

    Comment?

  9. Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins...Read the original story

    Sep 17, 2014 | Freshnews

    Adaptive Biotechnologies, a clinical stage diagnostics company that leverages Next Generation Sequencing to profile the adaptive immune system, is pleased to announce the appointment of Brian Hansen as Chief Commercial Officer . The addition of Brian to the Company's expanding Executive Leadership Team follows recent key hires from leading global healthcare companies, including Dean Schorno and Kathleen Determann from Genomic Health and Sean Nolan from Microsoft's Healthvault.

    Comment?

  10. Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins...Read the original story

    Sep 16, 2014 | Freshnews

    Adaptive Biotechnologies, a clinical stage diagnostics company that leverages Next Generation Sequencing to profile the adaptive immune system, is pleased to announce the appointment of Brian Hansen as Chief Commercial Officer . The addition of Brain to the Company's expanding Executive Leadership Team follows recent key hires from leading global healthcare companies, including Dean Schorno and Kathleen Determann from Genomic Health and Sean Nolan from Microsoft's Healthvault.

    Comment?

  11. Genomic Health CEO Unloads $89,460 in StockRead the original story

    Sep 15, 2014 | AmericanBankingNews.com

    Genomic Health CEO Kimberly J. Popovits sold 3,000 shares of Genomic Health stock on the open market in a transaction dated Thursday, September 11th. The shares were sold at an average price of $29.82, for a total transaction of $89,460.00.

    Comment?

  12. Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomicsRead the original story

    Sep 12, 2014 | Freshnews

    Genomic Health, Inc. today announced that PharmacoEconomics published positive results from a health economic analysis suggesting that use of the Oncotype DX colon cancer test may result in a significant reduction in direct medical costs and improve patient quality of life by helping them avoid side effects of unnecessary treatment. "By providing quantitative information which has not been available with conventional measures, as demonstrated in this analysis, the Oncotype DX colon cancer test is likely to lead to both savings in direct medical costs and improved patient well-being," said Steven Alberts, M.D., chair, division of Medical Oncology at the Mayo Clinic, Rochester, Minn.

    Comment?

  13. Genomic Health Coo G Bradley Cole Sells 4,700 SharesRead the original story

    Sep 10, 2014 | AmericanBankingNews.com

    Genomic Health COO G Bradley Cole unloaded 4,700 shares of Genomic Health stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $30.09, for a total value of $141,423.00.

    Comment?

  14. Genomic Health to present positive results from nine studies of Oncotype DXRead the original story

    Sep 9, 2014 | Theflyonthewall.com

    Genomic Health to present positive results from nine studies of Oncotype DX Genomic Health announced that results from nine studies of Oncotype DX in prostate, breast and renal cancers will be presented at the European Society for Medical Oncology, or ESMO, 2014 Congress in Madrid, September 26 - 30. Included in the program is the first presentation of strongly positive results from an additional large independent clinical validation study of the Oncotype DX prostate cancer test, conducted in collaboration with the Center for Prostate Disease Research, Rockville.

    Comment?

  15. Genomic Health Announces Presentation of Positive Results from Latest ...Read the original story

    Sep 9, 2014 | Applied Clinical Trials

    Genomic Health Announces Presentation of Positive Results from Latest Prostate Cancer Clinical Validation Study at the European Society for Medical Oncology 2014 Congress Genomic Health Announces Presentation of Positive Results from Latest Prostate Cancer Clinical Validation Study at the European Society for Medical Oncology 2014 Congress /PRNewswire/ -- Genomic Health, Inc. today announced that results from nine studies of Oncotype DX in prostate, breast and renal cancers will be presented at the European Society for Medical Oncology 2014 Congress in - 30. Included in the program is the first presentation of strongly positive results from an additional large independent clinical validation study of the Oncotype DX prostate cancer test, conducted in collaboration with the Center for Prostate Disease Research, This new study demonstrates the test's ability to predict a rise in ... (more)

    Comment?

  16. Societal cost-effectiveness analysis of the 21-gene assay in...Read the original story

    Sep 5, 2014 | BioMed Central

    Breast-cancer incidence and mortality have been increasing in Japan. Japanese-specific clinical validity and utility data for the 21-gene assay Breast Cancer Assay; Genomic Health, Inc., Redwood City, USA) are now available.

    Comment?

  17. Genomic Health Receives Average Recommendation of "Hold" from AnalystsRead the original story

    Aug 29, 2014 | AmericanBankingNews.com

    Genomic Health has received a consensus rating of "Hold" from the ten brokerages that are covering the stock, American Banking and Market News reports .

    Comment?

  18. Molecular diagnostics pioneer and NanoString chief medical officer diesRead the original story

    Aug 27, 2014 | Business Journal

    ... had been chief medical officer at NanoString since 2011. He previously held a series of medical positions at Genomic Health , and also held senior product and development positions at several other pharmaceutical and biotech companies.

    Comment?

  19. New England BiolabsA Introduces New Ribosomal RNA Depletion Technology from Genomic HealthRead the original story

    Aug 19, 2014 | Freshnews

    New England Biolabs, Inc. ) today announced that NEB has exclusively in-licensed rights from Genomic Health, Inc. to its technology for the depletion of abundant RNAs, which is instrumental to performing sensitive RNA-seq experiments at a lower cost.

    Comment?

  20. Genomic Health EVP Steven Shak Unloads 13,348 SharesRead the original story

    Aug 17, 2014 | AmericanBankingNews.com

    Genomic Health EVP Steven Shak unloaded 13,348 shares of the stock in a transaction dated Thursday, August 14th.

    Comment?